| 1 | 11C-PBR28 | - | - | - | - | 2件: 6 6, 13 |
| 2 | 11C]PBR28 | - | - | - | - | 1件: 6 6 |
| 3 | 18F-PBR06 | - | - | - | - | 1件: 17 17 |
| 4 | 18F-PM-PBB3 | - | - | - | - | 1件: 13 13 |
| 5 | 4-PBA | - | - | - | - | 1件: 231 231 |
| 6 | [18F] PBR06 | - | - | - | - | 2件: 6 6, 13 |
| 7 | [18F]PBR06 | - | - | - | - | 1件: 2 2 |
| 8 | [C-11]PBR28 | - | - | - | - | 1件: 13 13 |
| 9 | [F-18]PBR06 | - | - | - | - | 1件: 13 13 |
| 10 | ADA PBSC | - | - | - | - | 1件: 65 65 |
| 11 | ETIMS (EDC-fixed autologous PBMCs coupled with 7 immunodominant myelin peptides in MS patients) | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 |
| 12 | Gene transduced PBL and/or gene transduced HSC | - | - | - | - | 1件: 65 65 |
| 13 | PB | - | - | - | - | 2件: 67 67, 225 |
| 14 | PB006 | - | - | - | - | 1件: 13 13 |
| 15 | PB1046 | - | - | - | - | 1件: 86 86 |
| 16 | PB1046 Injection | - | - | - | - | 1件: 113 113 |
| 17 | PB1046 Subcutaneous Injection | - | - | - | - | 1件: 86 86 |
| 18 | PB1046, VIP-ELP1-120, Vasomera | - | - | - | - | 1件: 86 86 |
| 19 | PBA | - | - | - | - | 1件: 231 231 |
| 20 | PBF-509 | - | - | - | - | 1件: 6 6 |
| 21 | PBF-677 | - | - | - | - | 1件: 97 97 |
| 22 | PBF-999 | - | - | - | - | 1件: 8 8 |
| 23 | PBF-999 / 160 mg | - | - | - | - | 1件: 8 8 |
| 24 | PBF-999 / 320 mg | - | - | - | - | 1件: 8 8 |
| 25 | PBFT02 | - | - | - | - | 1件: 127 127 |
| 26 | PBGM01 | - | - | - | - | 1件: 19 19 |
| 27 | PBI4050 | - | - | - | - | 2件: 85 85, 299 |
| 28 | PBKR03 | - | - | - | - | 1件: 19 19 |
| 29 | PBMC autotransplantation | - | - | - | - | 1件: 2 2 |
| 30 | PBT2 | - | - | - | - | 1件: 8 8 |
| 31 | Pemziviptadil (PB1046) Injection | - | - | - | - | 1件: 86 86 |
| 32 | RAAV2/5-PBGD vector dosage 1 | - | - | - | - | 1件: 254 254 |
| 33 | RAAV2/5-PBGD vector dosage 2 | - | - | - | - | 1件: 254 254 |
| 34 | RAAV2/5-PBGD vector dosage 3 | - | - | - | - | 1件: 254 254 |
| 35 | RAAV2/5-PBGD vector dosage 4 | - | - | - | - | 1件: 254 254 |
| 36 | Vasomera (PB1046) Injection | - | - | - | - | 1件: 86 86 |